TCRX
What one share of Tscan Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT).
Tscan Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$0.91 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.91 |
| Cash and investments | $0.77 |
| Debt | $0.25 |
| Book value | $0.53 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $1.18 | −$28.52 | $4.63 | −$7.93 | — | −$37.38 |
| 2021 | $0.87 | −$4.17 | $0.85 | −$5.03 | — | — |
| 2022 | $0.56 | −$2.75 | $0.18 | −$2.94 | — | $4.13 |
| 2023 | $0.32 | −$1.36 | $0.05 | −$0.98 | — | $2.30 |
| 2024 | $0.03 | −$1.14 | $0.03 | −$1.02 | — | $2.15 |
| 2025 | $0.08 | −$1.00 | $0.03 | −$1.08 | — | $0.95 |